Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999. "Reacquiring the commercial rights to ACTOS is Takeda's first opportunity to establish a commercial presence in Canada," said Daaron Dohler, general manager at Takeda Canada.
The details can be read here.
No comments:
Post a Comment